Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 18/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinpocetine SCHEMBL29364972 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL50081 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL6246968 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL10571708 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL20077503 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL7947532 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL20077534 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL21370424 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL21098929 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL29366611 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008098192-A2 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | MAIBACH TODD (US) | 2008-08-14 | — | — | WO | claimed |
| US-20020160939-A1 | Method of identification of inhibitors of PDE1C and methods of treatment of diabetes | MICHAELI TAMAR H (US) | 2002-10-31 | — | — | US | claimed |
| EP-4704983-A2 | TREATMENT OF MEMORY LOSS WITH PHOSPHODIESTERASE INHIBITORS | Cyrano Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12329753-B2 | Phosphodiesterase inhibitor treatment | CYRANO THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250009649-A1 | Implants for Loss of Taste and Smell | CYRANO THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240423907-A1 | Improved Nasal Administration of Pharmaceutical Formulations | CYRANO THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240423990-A1 | Nasal Spray for Phosphodiesterase Inhibitors | CYRANO THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240423908-A1 | Improved Nasal Administration of Parkinson's Therapeutics | CYRANO THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240398816-A1 | Gel Treatment for Loss of Taste and Smell | CYRANO THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2008075117-A1 | APOVINCAMINIC ACID OR ITS ETHYL ESTER DERIVATIVE FOR THE TREATMENT OF MICROANGIOPATHIES | RICHTER GEDEON NYRT. (HU) | 2008-06-26 | — | — | WO | disclosed |
| WO-2005044272-A1 | COMPOSITIONS AND METHODS FOR TREATING CELLULAR PROLIFERATION DISORDERS | SCOTTSDALE SCIENTIFIC DBA ALLERGY RESEARCH GROUP/NUTRICOLOGY, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050096369-A1 | Compositions and methods for treating cellular proliferation disorders | SCOTTSDALE SCIENTIFIC DBA ALLERGY RESEARCH GROUP/NUTRICOLOGY, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6812239-B2 | DETERMINING IF COMPOUND INHIBITS PHOSPHODIESTERASE 1C (PDE1C) IN PANCREATIC ISLET BETA-CELLS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2004-11-02 | — | — | US | disclosed |
| EP-1267862-A2 | METHODS AND COMPOSITIONS FOR IMPROVING SLEEP | Cellegy Canada Inc. (CA) | 2003-01-02 | — | — | EP | disclosed |
| US-20020160939-A1 | Method of identification of inhibitors of PDE1C and methods of treatment of diabetes | MICHAELI TAMAR H (US) | 2002-10-31 | — | — | US | disclosed |
| US-6417208-B1 | PANCREATIC ISLET BETA-CELL CULTURE AND DETECTION OF INHIBITOR OF PHOSPHODIESTERASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-07-09 | — | — | US | disclosed |
| WO-2001062290-A2 | METHODS AND COMPOSITIONS FOR IMPROVING SLEEP | CELLEGY CANADA INC. (CA) | 2001-08-30 | — | — | WO | disclosed |
| EP-0689844-A1 | Complexes of vinpocetine formed with cyclodextrins, process for their preparation and pharmaceutical compositions containing them | TECNIMEDE-SOCIEDADE TECNICO-MEDICINAL, S.A. (PT) | 1996-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | PDE1A 2676/4885MEN1 1105/4885LMNA 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.